JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Tumor therapy with Amanita phalloides (Death Cap): stabilization of mammary duct cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : TANG [HUMANITAS MEDICINE]
  • Volume 1, Issue 1,  2011, pp.5.1-5.3
  • Publisher : Association of Humanitas Medicine
  • DOI : 10.5667/tang.2011.0006
 Title & Authors
Tumor therapy with Amanita phalloides (Death Cap): stabilization of mammary duct cancer
Riede, Isolde;
  PDF(new window)
 Abstract
Molecular events that cause tumor formation enhance a number of HOX genes, called switch genes, coding for RNApolymeraseII transcription factors. Thus, in tumor cells, RNApolymeraseII is more active than in other somatic cells. Amanita phalloides contains amanitin which inhibits RNApolymeraseII. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. To widen the treatment spectrum, dilutions of Amanita phalloides, containing amanitin, are applied to a patient with mammary duct cancer. For monitoring tumormarkers, different doses of amanitin are applied. The former duplication time of tumor growth represented three months; however within a period of 18 months the patient can be stabilized without further growth of the tumor. There are also no severe symptoms, no liver damage and no continuous erythrocyte deprivation. This new principle of tumor therapy shows high potential to provide a medical treatment.
 Keywords
Amanita therapy;tumor therapy;breast cancer;mammary ducts cancer;hox genes;switch genes;
 Language
English
 Cited by
 References
1.
Barrett JC, Oshimura M, Koi M. Role of oncogenes and tumor suppressor genes in a multistep model of carcinogenesis. Symp Fundam Cancer Res. 1986;39:45-56.

2.
Bishop JM. Viral oncogenes. Cell. 1985;42(1):23-38. crossref(new window)

3.
Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71(4):701-708. crossref(new window)

4.
Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, Rao MK. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogen in human cancers. Oncogene. 2010;29:4971-4979. crossref(new window)

5.
Orlovsky K, Kalinkovich A, Rozovskaia T, Shezen E, Itkin T, Alder H, Ozer HG, Carramusa L, Avigdor A, Volinia S, Buchberg A, Mazo A, Kollet O, Largman C, Croce CM, Nakamura T, Lapidot T, Canaani E. Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci U S A. 2011;108(19):7956-7961. crossref(new window)

6.
Riede I. Proliferative genes induce somatic pairing defects in Drosophila melanogaster and allow replication. Cancer Genet Cytogenet. 1997;97(2):143-154. crossref(new window)

7.
Riede I. Switch Genes in Tumor Formation, Drosophila Information Service. 2004;87:54-59.

8.
Riede, I. Tumor Therapy with Amanita phalloides (Death Cap): Stabilization of B-Cell Chronic Lymphatic Leukemia. J Altern Complement Med. 2010;16(10):1129-1132. crossref(new window)

9.
Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene 2001;20(7):874-878. crossref(new window)

10.
Svingen T, Tonissen KF. Altered HOX gene expression in human skin and breast cancer cells. Cancer Biol Ther. 2003;2:518-523. crossref(new window)

11.
Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 2010;70(21):8487-8497. crossref(new window)